Format

Send to

Choose Destination
J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):85-106. doi: 10.1089/jop.2017.0041. Epub 2017 Aug 18.

Targets of Neuroprotection in Glaucoma.

Author information

1
North Texas Eye Research Institute, University of North Texas Health Science Center , Fort Worth, Texas.

Abstract

Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.

KEYWORDS:

drug targets; glaucoma; neuroprotection

PMID:
28820649
PMCID:
PMC5963639
DOI:
10.1089/jop.2017.0041
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center